Evidence map›Paper›PMID 32540978›Full record

ArticleAntimicrobial agents and chemotherapy2020

Orally Bioavailable Endochin-Like Quinolone Carbonate Ester Prodrug Reduces Toxoplasma gondii Brain Cysts.

J Stone Doggett, Tracey Schultz, Alyssa J Miller, Igor Bruzual, Sovitj Pou, Rolf Winter, Rozalia Dodean, Lev N Zakharov, Aaron Nilsen, Michael K Riscoe and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Legacy 4(1ACS infectious diseases · 2026
    Article
  4. A novel anti-Microbiology spectrum · 2026
    Article
  5. First In Silico Study of TwoInternational journal of molecular sciences · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Synthesis of Deuterated Endochin-Like Quinolones.Journal of labelled compounds & radiopharmaceuticals · 2024
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Structure-activity relationships ofExpert opinion on drug discovery · 2022
    Article
  16. Dual inhibition of theFrontiers in veterinary science · 2022
    Article
  17. Article
  18. Article
  19. Treatment of Human Babesiosis: Then and Now.Pathogens (Basel, Switzerland) · 2021
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

J Stone DoggettDivision of Infectious Diseases, Oregon Health and Science University School of Medicine, Portland, Oregon, USA doggettj@ohsu.edu.
Tracey SchultzDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Alyssa J MillerProgram in Cell and Molecular Biology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Igor BruzualDepartment of Hospital and Specialty Medicine, Veterans Affairs Portland Health Care System, Portland, Oregon, USA.ORCID 0000-0003-4155-7596
Sovitj PouDepartment of Hospital and Specialty Medicine, Veterans Affairs Portland Health Care System, Portland, Oregon, USA.
Rolf WinterDepartment of Hospital and Specialty Medicine, Veterans Affairs Portland Health Care System, Portland, Oregon, USA.
Rozalia DodeanDepartment of Hospital and Specialty Medicine, Veterans Affairs Portland Health Care System, Portland, Oregon, USA.
Lev N ZakharovDepartment of Chemistry, University of Oregon, Eugene, Oregon, USA.
Aaron NilsenDivision of Infectious Diseases, Oregon Health and Science University School of Medicine, Portland, Oregon, USA.
Michael K RiscoeDivision of Infectious Diseases, Oregon Health and Science University School of Medicine, Portland, Oregon, USA.
Vern B CarruthersDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
VA Portland Health Care System · USOregon Health & Science University · USUniversity of Michigan · USUniversity of Oregon · US

Funding

Optimizing ELQs for Treatment and Prevention of MalariaR01AI100569 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI Michael Kevin RISCOE · 2014 to 2026
$8.0M
Development of a Sustained Release Injectable Formulation for Long-Term Delivery of ELQsR01AI141412 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI RISCOE, MICHAEL KEVIN · 2019 to 2022
$3.2M
Pharmachin Optimization and TestingI01BX003312 · VA · PORTLAND VA MEDICAL CENTER · PI RISCOE, MICHAEL KEVIN · 2016 to 2025
–
Novel Therapeutic Strategies for ELQ-422, a preclinical Toxoplasmosis Drug CandidateI01BX004522 · VA · PORTLAND VA MEDICAL CENTER · PI Joseph Stone Doggett · 2019 to 2026
–
Development of the potent anti-malarial and anti-Toxoplasma drug, ELQ-316IK2BX002440 · VA · PORTLAND VA MEDICAL CENTER · PI DOGGETT, JOSEPH STONE · 2014 to 2018
–
BLRD VA I01 BX001421BLRD VA I01 BX003312BLRD VA I01 BX004522BLRD VA IK2 BX002440BLRD VA IK6 BX004857NIAID NIH HHS R01 AI100569NIAID NIH HHS R01 AI141412
6 · The paper itself

Abstract

Toxoplasmosis is a potentially fatal infection for immunocompromised people and the developing fetus. Current medicines for toxoplasmosis have high rates of adverse effects that interfere with therapeutic and prophylactic regimens. Endochin-like quinolones (ELQs) are potent inhibitors of

Indexed as

ProdrugsQuinolonesToxoplasmaToxoplasmosis, AnimalAnimalsBrainCarbonatesEstersMiceCarbonatesEstersProdrugsQuinolonesanimal modelscytochromesdrug discoveryelectron transportexperimental therapeuticsToxoplasma gondii

Identifiers

PMID32540978
PMCPMC7449172
OpenAlexW3034643500

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.